Rhytha Kasiraj
This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.
Role not yet determined Is this you? Add your title
Research Areas
Biography and Research Information
OverviewAI-generated summary
Rhytha Kasiraj's research focuses on the comparative analysis of targeted therapies in B-cell malignancies. Their work investigates the real-world outcomes of treatments such as Ibrutinib, Acalabrutinib, and Zanubrutinib, specifically examining mortality and toxicity rates. This research contributes to understanding the comparative effectiveness and safety profiles of these medications in patient populations.
Metrics
- Publications: 2
Selected Publications
-
POSTER: CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity (2026)
-
CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity (2026)
Collaboration Network
Top Collaborators
- CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity
- POSTER: CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity
- CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity
- POSTER: CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity
- CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity
- POSTER: CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity
- CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity
- POSTER: CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity
- CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity
- POSTER: CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity
- CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity
- POSTER: CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity
Similar Researchers
Based on overlapping research topics